Fighting cancer is considered one of the most important areas of research in medicine and immunology. Due to the ability of cancer cells to mutate and become resistant to available drugs, new scientific approaches, focused on molecular mechanisms of carcinogenesis, are needed. A new direction in cancer treatment has arisen, devoted to the adjuvant use of natural bioactive compounds in conventional chemotherapy. This kind of research is gaining more attention. In particular, fungi can be used not only as strong immunoceuticals but also as a source of potent metabolites, capable of penetrating cell membranes and interfering with particular signal transduction pathways linked to processes such as inflammation, cell differentiation and survival, carcinogenesis, and metastasis. One such a crucial pathway involved in the above-mentioned processes, is the activation of the nuclear transcription factor κB (NF-κB). This review compiles the available data on fungal metabolites, known to modulate the activity of NF-κB, thus demonstrating their potential use as novel anti-cancer agents in the rapidly advancing field of molecular therapy.
Introduction
Cancer is the second most predominant cause of death in the modern world, after cardiovascular diseases, taking many human lives every year. Depending on the stage of cancer progression, treatments include surgical operation, radiotherapy and chemotherapy. However, their side effects cause serious damage and suffering to patients. As an alternative to these treatment methods, immunotherapy is now gaining more attention than ever. Immunotherapy substantially reduces the side effects and the inherent pain of cancer sufferred by patients and helps to overcome cancer growth, even in the last stages of the disease.
Despite the observed success of most of the chemotherapeutic regimes, cellular adaptations have enabled tumor cells to evade many of these drugs. The nuclear transcription factor κB (NF-κB) is one of the factors responsible for cellular chemoresistance. It is a dimeric transcription factor belonging to the Rel/NF-κB family of transcription factors (1) (2) (3) (4) . The NF-κB complex is maintained in the cytoplasm in an inactive form by the inhibitory protein κB (IκBα), belonging to a family of inhibitory proteins, IκBs. The major activator of NF-κB is the IκB kinase complex (IKK). This complex is composed of two catalytic subunits, IKK-α and -ß and a regulatory subunit, IKK-γ (also known as NEMO) (2) . The NF-κB pathway is triggered by bacterial and viral infections as well as pro-inflammatory cytokines and chemokines [e.g., tumor necrosis factor α (TNF-α), lipopolysaccharide (LPS), interleukins (IL-1, IL-6)], all of which activate the IKK complex. After activation, the IKK complex phosphorylates NF-κB-bound IκBs, thereby targeting them for proteasomal degradation. Simultaneously, the NF-κB dimers are released and free to enter the nucleus where transcriptional activation of target genes begins (Fig. 1 ). These target genes are mainly immunosuppresive, inflammatory and anti-apoptotic genes ONCOLOGY REPORTS 19: 299-308, 2008 299 Fungal metabolites modulating NF-κ κB activity: An approach to cancer therapy and chemoprevention (Review) (1, 4) . For instance, NF-κB induces the expression of genes coding for antigen receptors on immune cells, adhesion molecules, pro-inflammatory cytokines or chemoattractants for inflammatory cells (5) . Moreover, the active NF-κB induces the transcription of a set of gene coding for antiapoptotic proteins such as c-IAP-1 and -2 that directly block caspase functions or indirectly induce their ubiquitination and proteasome-dependent degradation. Another antiapoptotic protein whose gene is under NF-κB control is c-FLIP that has a high homology with procaspase-8 but is without catalytic activity. Upon induction, c-FLIP associates with the TNF-receptor to compete with and block caspase-8 activation.
In spite of its anti-apoptotic function, NF-κB is also known to promote cell death under certain conditions. Most of the proapoptotic effects of NF-κB are due to the induction of gene coding for the death receptor Fas or its ligand FasL. For example, NF-κB can interfere with the p53 pathway for the pro-apoptotic protein Bax. Generally, NF-κB and p53 express opposite functions although p53 can be induced by NF-κB (5).
In addition, NF-κB is associated with most processes that are believed to lead to neoplastic development, including self-sufficiency in growth signals, insensitivity to growthinhibitory signals, evasion of apoptosis, limitless replicative potential, tissue invasion and metastasis and sustained angiogenesis (6) .
NF-κB is also known to be involved in mediating inflammation. Chronic inflammation has long been suggested as constituting a risk factor for a variety of epithelial cancers such as malignancies of the prostate, cervix, esophagus, stomach, liver, colon, pancreas and bladder. Indeed, more than 20% of all human cancers are caused by chronic infection or inflammatory states. Recent studies have highlighted the importance of the connection between NF-κB, inflammation and cancer and have underscored the value of therapies that regulate the activity of NF-κB for cancer therapy and chemoprevention in cases where chronic inflammation is the driven force for cancer initiation (7) .
It is clear now that the aberrant gene expression is a fundamental cause of many diseases, including cancer. The pharmacological modulation of the intracellular signal transduction pathways and the activation of transcription factors regulating gene expression represent an attractive therapeutic approach to such disorders. Therefore, a significant part of the our research is focused on the identification of new natural compounds interfering with signal transduction pathways, the elucidation of their specific mechanism of action at the molecular level, as well as the application and evaluation of new targets for a rational development of novel therapeutics to cancer.
It is well documented that fungi produce a large and varied number of biologically-active compounds that not only stimulate the immune system but also modulate specific cellular responses by interfering with particular signal transduction pathway (8) . For example, caffeic acid phenethyl ester (CAPE), which specifically inhibits DNA binding of the NF-κB and has shown some promising results in human breast cancer MCF-7 cells, was found to be produced by Agaricus bisporus, Lentinus edodes and Phellinus linteus (9, 10) . Moreover, a methanol extract of Fomes fomentarius was reported to inhibit the inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX) expression due to the down-regulation of the NF-κB binding activity to DNA (11) . A model of the classical NF-κB activation pathway. TNF-α binds to its specific receptor on the cell membrane (TNFR) and induces activation of the IKK kinase complex. Subsequently, the IKKß subunit phosphorylates the IκBα inhibitory protein releasing the NF-κB dimers (p65 and p50). IκBα is ubiquitinated and degraded in the proteasome, while NF-κB is transferred into the nucleus, where the expression of target genes begins, including the genes related to inflammation, anti-apoptosis, drug resistance and metastasis. A new IκBα is synthesized and inhibits NF-κB by translocating it back to the cytoplasm. In the presence of appropriate stimuli a new cycle of NF-κB activation will start again.
Panepoxydone, a compound isolated from Panus spp. but also found in Lentinus crinitus, interferes with the NF-κB-mediated signal transduction by inhibiting the phosphorylation of IκBα (12) . These reports demonstrate the fact that such substances can be used as molecular targets in malignant cells in order to combat certain cancers. Some of these substances are low-molecular-weight compounds that can penetrate the cell membrane. Among them there are lectins, lactones, terpenoids, alkaloids, antibiotics and metal chelating agents (13) . Fungi also contain a number of enzymes such as laccase, superoxide dismutase, glucose oxidase and peroxidases. It has been shown that such an enzyme therapy can also play an important role in cancer treatment preventing oxidative stress and inhibiting cell growth (14) .
Herein is the first attempt at summarizing the known data on fungal metabolites modulating the NF-κB activation pathway, which includes data on 26 fungal species known to produce bioactive substances interfering with the NF-κB function and their specific mechanisms of action and on fungal low-molecular-weight compounds that can penetrate the cell membrane and modulate NF-κB activation. Fungi also contain high-molecular-weight polysaccharides with significant biological activities. However, it is considered unlikely that such polysaccharides affect this mechanism. Furthermore, this review summarizes several known characteristics of additional fungal compounds and elaborates on their activities. This information may provide new insight into cancer therapy, demonstrating that fungi may serve as a promising natural source of anticancer therapeutics.
Fungal metabolites modulating NF-κ κB activity
Natural bio-products became popular in medicinal practice mainly because of their biological activity, which may be related to the nature of tumor-specificity and due to their novel chemical complexity. While there are examples where mushroom polysaccharides have demonstrated efficacy against specific types of cancer, such as in mono-therapy, the overwhelming successes have occurred when they were tested together with proven and accepted chemotherapeutic agents. The recent progress in fermentation, isolation and structure elucidation technologies has made research into the fungal secondary metabolism seem worthwhile. Based on these findings, an increasing amount of research on lowmolecular-weight fungal substances modulating intracellular transduction pathways and, in particular, the NF-κB activation pathway has already been undertaken.
For example, the medicinal mushroom Agrocybe aegerita exhibits anti-tumor and immunostimulating activities due to the presence of bioactive glucans (15, 16) . Further studies demonstrated that a lectin, isolated from the same mushroom, exerts anti-tumor effects via apoptosis induction and the expression of DNAse activity (17) . Also, COX-enzyme inhibitory and anti-oxidant activities of a fatty acid fraction, obtained from the same species, were reported (18) . Data on the screening of 28 crude mushroom extracts with an NF-κB modulating activity were also published (19) . The latter study described 15 mushroom extracts, which exhibited different effects on the IKBα level and these extracts were divided into four basic categories: i) extracts that inhibit the NF-κB function with a minor influence on IκBα phosphorylation and/or degradation, ii) extracts affecting IκBα phosphorylation and iii) degradation and iv) affecting both IκBα phosphorylation and degradation. Among these extracts, a crude ethyl acetate extract of A. aegerita culture liquid possessed a moderate inhibitory activity on both IκBα degradation and phosphorylation (Table I) .
The most potent mushroom and the strongest inhibitor of IκBα phosphorylation was Marasmius oreades. These results were the first reported data on M. oreades, demonstrating its anti-NF-κB effect (19) . It should be noted that previous studies on this fungus revealed the presence of agrocybin and drimane sesquiterpenes reported to induce anti-microbial and phytotoxic properties (20) . In a separate study (21) , it was demonstrated that an isolated lectin caused renal thrombotic microangiopathic lesions (Table I ). Although M. oreades was distinguished as the strongest inhibitor of IκBα phosphorylation, several other mushrooms, including Ganoderma sp., Pleurotus ostreatus and Schizophyllum commune exhibited similar activities (19) . All of them exerted considerable inhibitory effects on the phosphorylation of IκBα. Despite its effect on IκBα phosphorylation, Ganoderma sp. also slightly affected the degradation of IκBα.
Ganoderma is the most popular and well investigated genus among the medically active mushrooms. Many species of this genus possess anti-viral, anti-bacterial, anti-fungal, anti-cancer and immunostimulating activities and have been used in traditional Chinese medicine for thousands of years. These activities are due to the production of various metabolites such as terpenes, sterols, etc. Herein, only data on the in vitro and NF-κB-modulating effects of the most common species, G. lucidum, are included. Specifically, it was reported that an alcohol extract of this species induced G1 cell cycle arrest (22) . Further investigations established that a spore extract inhibited breast and prostate cancer cell proliferation in vitro (23) . However, only a few studies on the effect of Ganoderma spp. on the NF-κB activation pathway were conducted. It was reported that G. lucidum spores and the fruiting body (FB) extracts inhibited activator protein-1 (AP-1) and NF-κB (24, 25) . Recently, a G. lucidum organic extract was shown to interfere with the androgen receptor function, a molecular target implicated in prostate cancer development, inducing G1 arrest in androgen-dependent but not in androgenindependent prostate cancer cell lines (26) .
Schizophyllum commune is another common edible and medicinal mushroom, which appears to modulate the NF-κB activity through the inhibition of IκBα phosphorylation (19) . The main medicinal properties of this species are anti-tumor and immunomodulating, based on the production of the bioactive ß-glucan schizophyllan (27) .
Pleurotus ostreatus, which also showed an inhibitory effect on IκBα phosphorylation, is an edible mushroom possessing biological activity related to immunoenhancement and in vitro anti-cancer effects (19) . The first report showed anti-tumor activities of a P. ostreatus polysaccharide fraction (28) . It was noted that the anti-tumor properties of this species are related to the production of heteroglucans (27) . Another study showed that the P. ostreatus fruiting body extracts exhibited anti-tumor, hypocholesterol effects and hypotensive activity (29) . Similarly, it was recorded that the fruiting body ONCOLOGY REPORTS 19: 299-308, 2008 Table I. Fungal species affecting the NF-κB function, including additional fungal compounds and their activities. Table I . Continued. extracts of this mushroom possess cytostatic and antiinflammatory effects (30) . The in vitro studies on this species have a long history. Some P. ostreatus fermentation products were reported to exert in vitro activities against rodent mammary adenocarcinoma 755 (31), while a fruiting body extract suppressed aromatase activity (32) . Most recently, it was noted that low-molecular-weight substances from the crude mushroom extract inhibited the proliferation and differentiation of the K562 human leukemia cells (Table I ) (33) . Several bioactive metabolites with antibiotic effects were found in the fungal species Cytahus striatus. These are the diterpenoid derivate striatins and cyathins that exert antibacterial, fungicidal and cytotoxic properties (20, 34, 35) . The inhibition effects of striatins on the protein and RNA and DNA synthesis were reported (35) . Additionally, it was demonstrated that three out of four crude extracts of this species inhibited, dose-dependently and in very low concentrations, both IκBα phosphorylation and degradation (19) . According to this study, Trametes gibbosa is a strong inhibitor of both IκBα degradation and phosphorylation. The anti-tumor effects of the fruiting body hot water extracts and a ß-glucan were previously recorded (36) .
-----------------------------------------------------------------------------------------------------

A very potent modulator of the NF-κB activity was detected in the liquid culture extraction of the edible mushroom Pleurotus pulmonarius which was found to significantly inhibit the degradation of IκBα (19) . Although this was the first report on the NF-κB-modulating properties of the mushroom, there are many other studies showing its medicinal potential. For instance, it was shown to produce various biologically active substances such as proteins, glucans, and protein-containing polysaccharides, with anti-fungal, antitumor, anti-oxidant, anti-inflammatory and cytotoxic properties (20, 27, 37, 38) . Moreover, hematological and cardiovascular effects of this species were reported (39) .
Another medicinal mushroom with NF-κB inactivating abilities is Fomes fomentarius. A methanol extract of this species inhibited iNOS and COX expression due to the downregulation of the NF-κB binding activity to DNA (11) . In an independent study, it was shown that an ethyl acetate extract of the mushroom biomass strongly inhibited the degradation of IκBα and moderately affected IκBα phosphorylation (19) . However, these activities correlate with the previously reported anti-tumor and anti-microbial effects that are due mainly to the production of bioactive polysaccharides (27, 40, 41) .
Several popular and traditionally-used medicinal mushrooms were also investigated and reported to exhibit NF-κB-modulating properties. Among them, Agaricus bisporus, Lentinus edodes and Phellinus linteus were shown to produce CAPE, which specifically inhibits the NF-κB binding to DNA (Fig. 2) (9,10) . In addition, it was recorded that Agaricus bisporus and Lentinus edodes produce substances that suppress the aromatase activity (32) . Another edible and medicinal mushroom, which was found to suppress the activity of NF-κB and AP-1, is Agaricus brasiliensis s. Heinem (42) . A water extract of Hericium erinaceum, a wellknown mushroom with medicinal activities, reportedly enhances the activation of NF-κB (through its pro-apoptotic function) by inducing interleukin-1ß (IL-1ß) expression (43). Son et al reported that the water extract also induced macrophage activation leading to the iNOS gene expression followed by nitric oxide (NO) production through the activation of NF-κB (44) .
Panepoxydone and cycloepoxydon, biologically-active compounds that exert a potent NF-κB inhibitory activity, were isolated from the edible mushroom Panus conhatus (45) . Panepoxydone inhibited the TNF-α-or TPA-induced phosphorylation and degradation of IκB. Cycloepoxydon was shown to exert a potent NF-κB inhibitory activity in COS-1 cells (Fig. 2) . Panepoxydone was also found in Lentinus crinitus and was reported to interfere with the NF-κB-mediated signal by inhibiting the phosphorylation of IκBα (12) . Another fungus, known to modulate the NF-κB activity is the ascomycete Chaetomium subspirale. Its metabolite oxaspirodion demonstrated an ability to inhibit the phosphorylation of ERK1/2 (extracellular signal-regulated kinases) and the activation of NF-κB (Fig. 2, Table I ) (46) .
Sparassis crispa was known for its anti-tumor and immunostimulating activities, based on the production of bioactive ß-glucans (47) (48) (49) . Only recently has it been shown that a diethyl ether extract of this species inhibits the degradation of IκBα (19) . Similarly, Phallus impudicus was distinguished as another inhibitor of IκBα degradation in the latter study. Although scarce data for this species were previously presented, its anti-cancer potential has been ONCOLOGY REPORTS 19: 299-308, 2008 Table I. Continued. 
The IC 50 values are given according to the data by Petrova et al (19) . b Mushroom effects on IκBα phosphorylation and degradation are summarized and presented according to Petrova et al (19) . c References presenting the activity of Ganoderma lucidum.
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emphasized. More specifically, the anti-tumor effects include the prevention of thromboembolic complications in cancer patients and the reduction of metastases in Lewis lung carcinoma (27, 50, 51) . The same mode of action used in the screening study of Petrova et al was established for two other mushrooms, the basidiomycete Trametes zonata and the ascomycete Cordyceps sinensis (19) . The crude ethyl acetate extracts of both species appeared to be strong inhibitors of IκBα degradation but were also moderate inhibitors of IκBα phosphorylation. Previously, a mycelial extract of Trametes zonata was shown to inhibit the growth, promote apoptosis and induce the erythroid differentiation of the K562 (erythroleukemia) cell line, as well as inhibit the growth of the LNCaP (prostate cancer) cell line (52) . Regarding the activity of C. sinensis, it was reported to exert anti-tumor and immunomodulating properties, due to the production of polysaccharides, sterols, lipids, nucleosides and deoxynucleosides (53, 54) . It was also recorded that a polysaccharide fraction from an ethanol-precipitable aqueous extraction of that fungus inhibited the proliferation and differentiation of the human leukemic U937 cells (55) . Further studies on this species resulted in the isolation of bioactive sterols, which exhibited anti-tumor activities against various tumor cell lines such as the K562, Jurkat (T-lymphoblastic), HL-60 (promyelocytic leukemia), WM1341 (malignant melanoma) and RPMI (multiple myeloma) (56) . An ethanolic extract from this fungus as well as cordycepin, a newly-discovered bioactive compound, were reported to possess anti-oxidant and anti-tumor activities such as inhibiting cell proliferation, and inducing apoptosis in colorectal and hepatocellular cancer (57) . Another study demonstrated that a methanol extract of Cordyceps pruinosa suppresses inflammation through the inhibition of the NF-κB-dependent inflammatory gene expression. The methanol extract inhibited IL-1ß, TNF-α, NO and prostaglandin E 2 in vitro and in vivo. The extract inhibited these inflammatory mediators in the LPS-stimulated murine macrophage cell line RAW264.7 and primary macrophages by suppressing the gene expression of IL-1ß, TNF-α, iNOS and cyclooxygenase-2 (COX-2) through NF-κB inhibition (58) (Table I ). In another study (59) , cordycepin was identified as a major component of a butanol fraction obtained from Cordyceps militaris (Fig. 2) . The effect of cordycepin on the anti-inflammatory activities of the RAW264.7 macrophages was examined. Results revealed that cordycepin suppressed the TNF-α gene expression, IκBα phosphorylation and the nuclear translocation of p65. Moreover, the expression of COX-2 and iNOS were significantly decreased due to the down-regulation of the NF-κB activation, serine/therionine kinase (Akt) and p38 phosphorylation (59) .
The enhancement of macrophage activation was also demonstrated by a galactomannan obtained from a polar extract of Morchella esculenta carpophores. The galactomannan polysaccharide increased the NF-κB luciferase expression in THP-1 human monocytes to levels of 50% of those achieved by the LPS activation (58) .
A methanol extract obtained from Inonotus obliquus (MEIO) was studied for anti-inflammatory and antinociceptive properties in vivo and in vitro (60) . MEIO inhibited the DNA binding activity of NF-κB which was associated with the prevention of IκBa degradation and reduction of the nuclear p65 levels. This study indicated that the anti-inflammatory and anti-nociceptive activities of MEIO may be due to the inhibition of iNOS and the COX-2 expression through the down-regulation of the NF-κB binding activity (60) .
A proteoglycan isolated from Phellinus linteus was investigated for its properties to interfere with the phenotypic and functional maturation of dendritic cells (61) . This study revealed that the proteoglycan directly activated mitogenactivated protein kinases (MAPKs), such as ERK1/2 and p38 as well as NF-κB, thus inducing the maturation of dendritic cells via the NF-κB, ERK and p38 MAPK signal pathways (61) .
A water extract of Trametes versicolor containing polysaccharo-peptide (PSP) was reported to induce cell cycle arrest at the G 1 /S and G 2 /M phases and alterations of antiapoptotic and extracellular regulatory proteins in human the U-937 leukemia cells, resulting in the suppression of proliferation and increase in apoptosis (62) . In HL-60 leukemia cells, PSP decreased the levels of the p65 and p50 forms of NF-κB associated with the inhibition of the COX-2 expression. PSP increased the expression of STAT-1 (signal transducer and activator of transcription) and decreased the expression of ERK (62).
Perspectives
This review describes the current knowledge on the lowmolecular-weight fungal compounds, interfering with the NF-κB activation pathway. It is already clear that fungi, belonging to different ecological (parasites, saprotrophs, etc.) and taxonomic (Ascomycetes and Basidiomycetes) groups produce bioactive metabolites that not only stimulate the immune system but can also modulate specific cellular responses such as the NF-κB function. The Fungi kingdom covers about 82,000 species and many have yet to be discovered. There is no doubt that this group of organisms is one of the most diverse and holds numerous opportunities for science as well as for medical purposes.
Currently, only 26 fungal species have been found to affect the NF-κB function through different mechanisms. However, many of them still have unclear modes of action. The known data on their properties are based mainly on the activities of the crude fruit body, biomass or culture liquid extracts. Therefore, in order to investigate and establish the origin and structure of the active compounds on the one hand and their specific mechanisms of action on the other, further investigations are needed.
Fungi represent an immense source of bioactive substances with immunostimulating and anti-cancer properties that make them very potent natural supplements in cancer therapy. This fact continues to prompt molecular therapy, based on the application of low-molecular-weight compounds interfering with the intracellular signal transduction pathways and may provide a higher success in cancer treatment. Fungal metabolites can also affect such crucial cancer-related pathways as the NF-κB pathway, which seems to be a promising approach in the therapy of cancer. Thus, the activities of more and various fungal species are worth investigation in order to establish other, more potent fungal substances that can be reliable therapeutics for humans.
